Observe Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Observe Medical hat ein Gesamteigenkapital von NOK115.6M und eine Gesamtverschuldung von NOK53.8M, was einen Verschuldungsgrad von 46.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen NOK253.5M bzw. NOK137.9M.

Wichtige Informationen

46.6%

Verhältnis von Schulden zu Eigenkapital

NOK 53.85m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	NOK 13.68m
Eigenkapital	NOK 115.61m
Gesamtverbindlichkeiten	NOK 137.93m
Gesamtvermögen	NOK 253.54m

Jüngste Berichte zur Finanzlage

Recent updates

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Jun 27

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Sep 23

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Jun 07

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Feb 08

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Sep 11

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Mar 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: OBSRVDie kurzfristigen Aktiva des Unternehmens (NOK27.2M) decken seine kurzfristigen Passiva (NOK60.9M) nicht.

Langfristige Verbindlichkeiten: OBSRVDie kurzfristigen Vermögenswerte des Unternehmens (NOK27.2M) decken seine langfristigen Verbindlichkeiten (NOK77.0M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: OBSRVDie Nettoverschuldung im Verhältnis zum Eigenkapital (34.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: OBSRV Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 148.8% auf 46.6% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: OBSRV verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 5 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass OBSRV auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 5 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Observe Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Recent updates

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical Asa Announces CFO Changes

Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021)

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Observe Medical ASA Announces Executive Appointments

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020)

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: kr29.80

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: kr16.00

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: kr14.70

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: kr11.40

New 90-day low: kr11.90

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: kr12.00

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: kr13.20

Earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen